Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pliability × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 360 pembrolizumab 277 Prednisone 245 enzalutamide 240 Gemcitabine 231 Magnetic Resonance Spectroscopy 228 Radiotherapy 226 Nivolumab 213 Abiraterone Acetate 179 Cisplatin 174 Radiosurgery 167 Leuprolide 167 Sunitinib 150 Carboplatin 139 Specimen Handling 131 Androgen Antagonists 128 bicalutamide 124 Goserelin 123 Ipilimumab 113 Paclitaxel 110 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 104 apalutamide 102 Cyclophosphamide 100 Everolimus 95 Biopsy 94 Sorafenib 92 Bevacizumab 89 cabozantinib 88 abiraterone 88 atezolizumab 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04485767 2024-08-20

RESIST-ADT (Androgen Deprivation Therapy)

Dana-Farber Cancer Institute

Phase NA Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡